Learn More
Invitrogen™ Osteopontin Monoclonal Antibody (2F10), eBioscience™
Description
Description: The 2F10 monoclonal antibody recognizes human osteopontin (OPN), a secreted glycophosphoprotein expressed by multiple cell types, including leukocytes, fibroblasts, dendritic cells, macrophages, myoblasts, bone-forming cells, and epithelial cells. OPN is an extracellular matrix protein with multiple roles, including bone resorption and calcification, immune system regulation, wound healing, and tumorigenesis. Thrombin cleavage of OPN allows binding of integrin receptors, expressed by immune cells, and subsequent modulation of cell adhesion, migration, and survival. OPN is expressed in bones, teeth, placenta, blood vessels, kidney, and various tumors. Osteopontin has been identified as a potential therapeutic target in the treatment of autoimmune disease, cancer metastasis, bone mineralization diseases, and osteoporosis. Applications Reported: This 2F10 antibody has been reported for use in western blotting, immunohistochemical staining of formalin-fixed paraffin embedded tissue sections, and immunocytochemistry. Applications Tested: This 2F10 antibody has been tested by immunohistochemistry of formalin-fixed paraffin embedded human tissue using either low or high pH antigen retrieval and can be used at less than or equal to 5 μg/mL. This 2F10 antibody has been tested by immunocytochemistry of either methanol-fixed or formaldehyde-fixed and permeabilized human cells and can be used at less than or equal to 10 μg/mL. It is recommended that the antibody be...
Specifications
Specifications
| Antigen | Osteopontin |
| Applications | Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry |
| Classification | Monoclonal |
| Clone | 2F10 |
| Concentration | 0.5 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 0.09% sodium azide; pH 7.2 |
| Gene | SPP1 |
| Gene Accession No. | P10451 |
| Gene Alias | 2AR; 2b7; 44 kDa bone phosphoprotein; Apl-1; BNSP; Bone sialoprotein 1; Bone sialoprotein 1 (BSPI/BSP1); Bsp; BSPI; Calcium oxalate crystal growth inhibitor protein; CALPHA1 fusion; Early T lymphocyte activation 1 (ETA1); early T-lymphocyte activation 1; early T-lymphocyte activation 1 protein; Eta; ETA-1; HGNC:11255; immunoglobulin alpha 1 heavy chain constant region fusion protein; MGC110940; Minopontin; nephropontin; Op; Opn; Opnl; OSP; osteopontin; osteopontin/immunoglobulin alpha 1 heavy chain constant region fusion protein; osteopontin-like protein; PSEC0156; Ric; Secreted phosphoprotein 1; secreted phosphoprotein 1 (osteopontin bone sialoprotein I early T lymphocyte activation 1); secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1); Secreted phosphoprotein 1 (SPP1); secreted phosphoprotein 1 variant 6; Sialoprotein (osteopontin); SPP1; SPP-1; SPP1/CALPHA1 fusion; unnamed protein product; urinar; urinary stone protein; Uropontin |
| Show More |
Safety and Handling
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.